Navigation Links
Salugen to Present Research on Generational Associations of Reward Deficiency Syndrome at XVth World Congress on Psychiatric Genetics
Date:10/8/2007

SAN DIEGO, Oct. 8 /PRNewswire/ -- Salugen, Inc., a personalized health and wellness company will present its research entitled: Generational Association Studies of Dopaminergic Genes (DRD1, DRD2, DAT1, & DBH) In Reward Deficiency Syndrome (RDS): A Paradigm Shift In Selecting Appropriate Phenotypes For Reward Dependence Behaviors at the XVth World Congress on Psychiatric Genetics October 7 - 11, 2007 in New York City, NY.

Dr. Kenneth Blum, Chief Scientific Officer of Salugen will discuss the generational association of genes associated with Reward Deficiency Syndrome (RDS). Numerous studies have revealed an association between certain dopaminergic gene polymorphisms and a number of reward dependent behaviors including addictive, compulsive and impulsive tendencies. These interrelated reward-dependent behaviors involving dopaminergic genes have been classified as RDS.

Additionally, he will present findings corresponding to multi-factorial phenotypes associated with the genes including ADHA, alcoholism, cocaine dependence, intravenous drug dependence, carbohydrate binging, smoking, hyperactivity, sex addiction, pathological violence, Tourette Syndrome, autism, and other personality disorders in an experimental group of 55 subjects derived from up to five generations of two independent multiple- affected families.

Salugen CEO Brian Meshkin states, "We are pleased to present Salugen's continued research on RDS. These findings aid us in furthering the clinical application of the research to assist those with a genetic predisposition to conditions associated with RDS."

Salugen currently markets DNA-customized nutritional solutions under three brands, GenoTrim(TM) for weight management (http://www.GenoTrim.com), SpaGen(TM) for optimal health and wellness (http://www.SpaGen.com) and Haveos(TM) for substance abuse attenuation.

About Saluge
'/>"/>

SOURCE Salugen, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
2. Researchers Present Ways To Reduce The Risk Of Dementia
3. Researchers Present Data Regarding The Efficiency Of Herbs
4. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
5. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
6. Drug Reactions First Present Themselves In The Mouth
7. Reminiscing Into The Past Makes You Dissatisfied With The Present
8. Living In The Past Indicates Dissatisfaction With Present
9. Movies Represent Coma In A Wrong Way
10. Onchocerciasis: Presentation And Treatment
11. Researchers Warn That Routine Physical Examination Could Miss Breech Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Reinberg HealthDay Reporter FRIDAY, ... should reassure the millions of American women who have migraine: ... "There is no association between migraine and breast cancer ... medicine at Harvard Medical School. "There is no positive association, ... no protective effect either." About 18 percent of American ...
(Date:12/15/2014)... The increase in prevalence of disabling hearing loss ... which is contributing to the growth in the global audiological ... of hearing loss and balance disorders are known as audiological ... speaker and amplifier. The global market is expected to grow ... period from 2014 to 2019. Some of the factors which ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Emergo Group, ... in 26 countries in North and South America, Europe, ... responses from industry participants for its 2015 Medical Device ... order to identify upcoming business and market trends as ... , The survey targets areas including:, , ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 At the ... organizations AutismOne and Focus Autism ... attendees with research on the effects of toxins to ... and intervention information. , Luminaries such as Dr. ... from abroad with esteemed, credentialed colleagues of the United ...
(Date:12/15/2014)... 2014 Kenmode Precision Metal Stamping has ... Director of Quality Assurance. He brings more than ... and certifications for manufacturers in the U.S. and abroad. ... Quality Manager at Sonoco Products Company in the Protective ... and Quality Assurance Manager for Prince Industries, all in ...
Breaking Medicine News(10 mins):Health News: No Link Between Migraine, Breast Cancer Risk, Study Says 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4Health News:Emergo’s Annual Survey Assessing the State of the Medical Device Industry Now Open 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3Health News:Kenmode Precision Metal Stamping Appoints Abid Rashid as Director of Quality Assurance 2
... vaccine is the first 5-in-1 pediatric combination for, immunization against ... ... b (Hib) -, SWIFTWATER, Pa. and LYON, France, June ... announced today,that the U.S. Food and Drug Administration (FDA) has ...
... AM ET MONDAY JUNE 23, 2008 , LOW SOCIOECONOMIC ... Cancer patients with low socioeconomic status (SES) have more advanced ... higher risk of dying in the five years following cancer ... appear in the August 1, 2008 issue of CANCER ...
... can prevent unnecessary accidents, experts say , , SUNDAY, June ... can greatly reduce the risk of serious head, spinal ... and recreational activities, says the American Association of Neurological ... head injuries treated in U.S. hospital emergency rooms in ...
... under 80, could ease expected worldwide shortfall of supplies , , ... called HBOC-201 proved safe and effective in a six-week Phase ... In all, 688 patients, ages 18 and older, who had ... (about one pint) or an equivalent one unit (65 grams) ...
... earlier treatment options for patients -, ... Millennium,Pharmaceuticals, The Takeda Oncology Company, and ... announced that the U.S. Food,and Drug Administration ... multiple myeloma (MM). The Company,s co-development partner,Johnson ...
... SAN FRANCISCO, June 20 The San Francisco,Medical Society ... in,Medical/Health Reporting." This $1,000 award is presented each ... good work of California reporters,from television, radio and ... 30, 2008 for the 2009 award., A ...
Cached Medicine News:Health News:U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R) 2Health News:U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R) 3Health News:U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R) 4Health News:U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R) 5Health News:Risk of death after cancer diagnosis; shift in stage of breast cancer diagnosis 2Health News:Risk of death after cancer diagnosis; shift in stage of breast cancer diagnosis 3Health News:Risk of death after cancer diagnosis; shift in stage of breast cancer diagnosis 4Health News:Risk of death after cancer diagnosis; shift in stage of breast cancer diagnosis 5Health News:Head Injuries All Too Common in Summer Play 2Health News:Blood Substitute Found Safe in Large Phase III Trial 2Health News:FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma 2Health News:FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma 3Health News:FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma 4Health News:FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma 5Health News:FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma 6Health News:SFMS David Perlman Award For Excellence in Medical/Health Reporting Recognizes Local Reporters 2
(Date:12/17/2014)... 2014 Los beneficios y ganancias ... nivel de gasto en investigación y desarrollo   ... 30 de septiembre de 2014) ZEISS aumentó sus ingresos ... euros (año anterior: 4.190 millones de euros) a pesar ... (EBIT) crecieron un 14 por ciento, a 360 millones ...
(Date:12/17/2014)... HOLBROOK, N.Y. , Dec. 17, 2014 /PRNewswire/ ... that The Depository Trust Company (DTC) has made ... the Deposit Chill on the Company,s stock effective ... of Northstar,s common stock for depository and book ... and the Company is now once again fully ...
(Date:12/17/2014)... MILAN , December 17, 2014 ... becoming nothing less than a hub of information concerning the ... A further addition to the recently launched ... world and has now been enriched by a new chapter ... A richly detailed and panoramic hub on ...
Breaking Medicine Technology:ZEISS confirma su posición en un entorno difícil 2Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3
... - GenVec, Inc.,(Nasdaq:GNVC) announced today data from ... of the American Association of Cancer,Research (AACR) ... systems,to deliver the gene for tumor necrosis ... (TNFerade),is an adenovector, or DNA carrier, which ...
... 2007 /PRNewswire-FirstCall/ --,Telik, Inc. announced the presentation ... trial of the triplet combination of TELCYTA(R),(canfosfamide ... treatment of advanced non-small cell lung cancer. ... in both progression-free survival and overall survival,in ...
Cached Medicine Technology:GenVec Announces New Research at AACR on Selectivity and Mechanism,of Action of TNF-Based Anti-Cancer Therapy 2GenVec Announces New Research at AACR on Selectivity and Mechanism,of Action of TNF-Based Anti-Cancer Therapy 3Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer 2Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer 3Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer 4
... The Cholestech LDX System, using patented, innovative ... glucose and ALT in only 5 minutes ... ALT test, you can get immediate liver ... capabilities is not the only advantage to ...
The Strep A Rapid Test Strip is a rapid chromatographic,immunoassay for the qualitative detection of Strep A antigen,from throat swab specimens to aid in the diagnosis of Group A,Streptococcal ...
SAS Strep A Test is a rapid visual test for the presumptive qualitative detection of Group A Streptococcal antigen from throat swab specimens. Group A streptococcus is the principal cause of respirat...
HemataSTAT II has a manual reader. It uses both 0.5 and 1.1 ID capillary tubes., , Spins in just 60 seconds , Built-in reader with LCD display , Accuracy comparable to NCCLS reference method , Lid lo...
Medicine Products: